«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 17

Page:

3354-3359

Research Field:

Publishing date:

Info

Title:

Clinical research progress of immune checkpoint inhibitor neoadjuvant treatment of stage ¢ñ-¢ó non-small cell lung cancer

Author(s):

SHAO Yanan; ZHANG Yue; QIAO Xinyi; WU Yunjiao; WANG Meng

Harbin Medical University Cancer Hospital£¬Heilongjiang Harbin 150001£¬China.

Keywords:

NSCLC; neoadjuvant therapy; ICIs; MPR; pCR

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2024.17.031

Abstract:

Non-small cell lung cancer is one of the leading causes of cancer-related deaths worldwide.Although complete surgical resection provides the best chance of cure for these patients,many of patients will relapse after surgery.Usually requires neoadjuvant treatment before surgery.The neoadjuvant treatment of non-small cell lung cancer has progressed slowly in recent years.With the emergence of immune checkpoint inhibitors for locally advanced and metastatic lung cancer,its application range has gradually expanded from advanced to preoperative treatment,representing the treatment of non-small cell lung cancer a gradual increase in means.In order to evaluate its efficacy and safety in neoadjuvant therapy,it is becoming more and more important to conduct related clinical studies.This article reviews the clinical research progress of immune checkpoint inhibitor neoadjuvant therapy in stage ¢ñ-¢ó non-small cell lung cancer,the exploration of related efficacy evaluation standards and predictive biomarkers,and the problems that need to be solved in the future.

References:

£Û1£ÝSIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021£ÛJ£Ý.CA Cancer J Clin,2021,71:7-33.
£Û2£ÝSUN D,HU J,LI X,et al.Real-world surgical treatment patterns and clinical outcomes in patients with stages ¢ña-¢óa non-small cell lung cancer:a retrospective multicentric observational study involving 11958 patients£ÛJ£Ý.J Cancer Res Clin Oncol,2023,149(11): 8213-8223.
£Û3£ÝARRIAGADA R,AUPERIN A,BURDETT S,et al.Adjuvant chemotherapy,with or without postoperative radiotherapy,in operable non-small-cell lung cancer:two meta-analyses of individual patient data£ÛJ£Ý.Lancet,2010,375(9722):1267-1277.
£Û4£ÝROBERT C.Is earlier better for melanoma checkpoint blockade£ÛJ£Ý.Nat Med,2018,24(11):1645-1648.
£Û5£ÝÁõÓêÌÒ,¸ßÓíË´,ëÓÑÉú£¬µÈ.³ÌÐòÐÔϸ°ûËÀÍöµ°°×1µ¥¿¹ÁªºÏ»¯ÁÆÔÚ¢òÆں͢óÆÚ·ÇСϸ°û·Î°©Êõǰи¨ÖúÖÎÁÆÖеÄÁÆЧºÍ°²È«ÐÔ£ÛJ£Ý.ÖлªÖ×ÁöÔÓÖ¾,2020,42(6):480-485. LIU YT,GAO YS,MAO YS,et al.The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage ¢ò-¢ó non-small cell lung canceer£ÛJ£Ý.Chinese Journal of Oncology,2020,42(6):480-485.
£Û6£ÝHUANG Z,WU Z,QIN Y,et al.Perioperative safety and feasibility outcomes of stage ¢óa-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy:a retrospective study£ÛJ£Ý.Ann Transl Med,2021,9(8):685.
£Û7£ÝFORDE PM,CHAFT JE,WILLIAM WN,et al.Neoadjuvant PD-1 blockade in resectable lung cancer£ÛJ£Ý.N Engl J Med,2018,378(21):1976-1986.
£Û8£ÝKRIS MG£¬FAIVRE-FINN C£¬KORDBACHEH T,et al.Making checkpoint in-hibitors part of treatment of patients with locally advanced lung cancers:the time is now£ÛJ£Ý.Am Soc Clin Oncol Educ Book,2020,40:1-12£®
£Û9£ÝCASCONE T,WILLIAM WN JR,WEISSFERDT A,et al.Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer:the phase 2 randomized NEOSTAR trial£ÛJ£Ý.Nat Med,2021,27(3):504-514.
£Û10£ÝBAKOS O,LAWSON C,ROULEAU S,et al.Combining surgery and immunotherapy:turning an immunosuppressive effect into a therapeutic opportunity£ÛJ£Ý.J Immunother Cancer,2018,6(1):86.
£Û11£ÝCOTTRELL TR,THOMPSON ED,FORDE PM,et al.Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma:a proposal for quantitative immune-related pathologic response criteria (irPRC)£ÛJ£Ý.Ann Oncol,2018,29(8):1853-1860.
£Û12£ÝLIU J,BLAKE SJ,YONG MCR,et al.Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease£ÛJ£Ý.Cancer Discov,2016,6(12):1382-1399.
£Û13£ÝBOTT MJ,YANG SC,PARK BJ,et al.Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer£ÛJ£Ý.J Thorac Cardiovasc Surg,2019,158(1):269-276.
£Û14£ÝGANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2018,378(22):2078-2092.
£Û15£ÝRECK M,RODRIGUEZ-ABREU D,ROBINSON AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2016,375(19):1823-1833.
£Û16£ÝPROVENCIO M,NADAL E,INSA A,et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM):an open-label,multicentre,single-arm,phase 2 trial£ÛJ£Ý.Lancet Oncol,2020,21(11):1413-1422.
£Û17£ÝCARPENTER KJ,VALFORT AC,STEINAUER N,et al.LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer£ÛJ£Ý.Sci Rep,2019,9(1):19530.
£Û18£ÝPALMERO R,VILARI£ÎO N,NAVARRO-MART¦PN A,et al.Induction treatment in patients with stage ¢ó non-small cell lung cancer£ÛJ£Ý.Transl Lung Cancer Res,2021,10(1):539-554.
£Û19£ÝBRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2015,373(2):123-135.
£Û20£ÝBORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2015,373(17):1627-1639.
£Û21£ÝFEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezoli-zumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a mul-ticentre,open-label,phase 2 randomised controlled trial£ÛJ£Ý.Lancet,2016,387(10030):1837-1846.
£Û22£ÝRITTMEYER A,BARLESI F,WATERKAMP D,et al.Atezolizu-mab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicenter randomised controlled trial£ÛJ£Ý.Lancet,2017,389(10066):255-265.
£Û23£ÝRIZVI H,SANCHEZ-VEGA F,CHATILA W,et al.Molecular determinants of response to antiprogrammed cell death (PD-1£© and anti-programmed death-ligand (PD-L1£© blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing£ÛJ£Ý. J Clin Oncol,2018,36(7):633-641.
£Û24£ÝHELLMANN MD,NATHANSON T,RIZVI H,et al.Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer£ÛJ£Ý.Cancer Cell,2018,33(5):843-852.
£Û25£ÝOLMEZ I,DONAHUE BR,BUTLER JS,et al.Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis£ÛJ£Ý.Lung Cancer,2010,70(2):174-179.
£Û26£ÝDEMPKE WCM,FENCHEL K,DALE SP.Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree£ÛJ£Ý.Transl Lung Cancer Res,2018,7(Suppl 3):S275-S279.
£Û27£ÝYARCHOAN M,HOPKINS A,JAFFEE EM.Tumor mutational burden and response rate to PD-1 inhibition£ÛJ£Ý.N Engl J Med,2017,377(25):2500-2501.
£Û28£ÝGOMPELMANN D,SAROVA P,MOSLEH B,et al.PD-L1 assessment in lung cancer biopsies-pitfalls and limitations£ÛJ£Ý.Int J Biol Markers,2024,39(1):3-8.
£Û29£ÝYONEDA K,KUWATA T,KANAYAMA M,et al.Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer£ÛJ£Ý.Br J Cancer,2019,121(6):490-496.
£Û30£ÝHU J,ZHANG L,XIA H,et al.Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing£ÛJ£Ý.Genome Med,2023,15(1):14.
£Û31£ÝCHAUDHURI AA,CHABON JJ,LOVEJOY AF,et al.Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling£ÛJ£Ý.Cancer Discov,2017,7(12):1394-1403.
£Û32£ÝABBOSH C,BIRKBAK NJ,WILSON GA,et al.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution£ÛJ£Ý.Nature,2017,545(7655):446-451.
£Û33£ÝEISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)£ÛJ£Ý.Eur J Cancer,2009,45(2):228-247.
£Û34£ÝHELLMAN MD,CIULEANU TE,PLUZANSKI A,et al.Nivolu-mab plus ipilimumab in lung cancer with a high tumor mutational burden£ÛJ£Ý.N Engl J Med,2018,378(22):2093-2104.
£Û35£ÝPATAER A,KALHOR N,CORREA AM,et al.Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy£ÛJ£Ý.J Thorac Oncol,2012,7(5):825-832.
£Û36£ÝRICE JD£¬HEIDEL J£¬TRIVEDI JR£¬et al.Optimal surgical timing after neoadjuvant therapy for stage ¢ó a non small cell lung cancer£ÛJ£Ý.Ann Thorac Surg,2020,109(3):842-847.

Memo

Memo:

-

Common functions

Last Update: 2024-07-31